Sutureless Fixation of Amniotic Membrane for Therapy of Ocular Surface Disorders by Kotomin, Ilya et al.
RESEARCH ARTICLE
Sutureless Fixation of Amniotic Membrane
for Therapy of Ocular Surface Disorders
Ilya Kotomin1, Monika Valtink2, Kai Hofmann3, Annika Frenzel4, Henning Morawietz4,5,
CarstenWerner5,6, Richard H. W. Funk2,5, Katrin Engelmann1,3,5*
1 Department of Ophthalmology, Klinikum Chemnitz gGmbH, Chemnitz, Germany, 2 Institute of Anatomy,
Medical Faculty Carl Gustav Carus, TU Dresden, Dresden, Germany, 3 Deutsche Gesellschaft für
Gewebetransplantation, DGFG, Hannover, Germany, 4 Division of Vascular Endothelium and
Microcirculation, Department of Medicine III, TU Dresden, Dresden, Germany, 5 CRTD / DFG-Center for
Regenerative Therapies Dresden—Cluster of Excellence, Dresden, Germany, 6 Leibniz-Institut für
Polymerforschung Dresden e.V., Dresden, Germany
* k.engelmann@skc.de
Abstract
Amniotic membrane is applied to the diseased ocular surface to stimulate wound healing
and tissue repair, because it releases supportive growth factors and cytokines. These ef-
fects fade within about a week after application, necessitating repeated application. Gener-
ally, amniotic membrane is fixed with sutures to the ocular surface, but surgical intervention
at the inflamed or diseased site can be detrimental. Therefore, we have developed a system
for the mounting of amniotic membrane between two rings for application to a diseased ocu-
lar surface without surgical intervention (sutureless amniotic membrane transplantation).
With this system, AmnioClip, amniotic membrane can be applied like a large contact lens.
First prototypes were tested in an experiment on oneself for wearing comfort. The final sys-
tem was tested on 7 patients in a pilot study. A possible influence of the ring system on the
biological effects of amniotic membrane was analyzed by histochemistry and by analyzing
the expression of vascular endothelial growth factor-A (VEGF-A), hepatocyte growth factor
(HGF), fibroblast growth factor 2 (FGF 2) and pigment epithelium-derived factor (PEDF)
from amniotic membranes before and after therapeutic application. The final product,
AmnioClip, showed good tolerance and did not impair the biological effects of amniotic
membrane. VEGF-A and PEDF mRNA was expressed in amniotic membrane after storage
and mounting before transplantation, but was undetectable after a 7-day application period.
Consequently, transplantation of amniotic membranes with AmnioClip provides a suture-
less and hence improved therapeutic strategy for corneal surface disorders.
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Introduction
Amniotic membrane (AM) transplantation was first introduced in the 1940ies and was a tre-
mendous advancement for the therapy of persisting corneal defects [1]. In the 1990s, the devel-
opment of methods to preserve AM further supported this therapeutic approach. Membranes
were now able to be stored for several months, allowing for scheduled surgical interventions
[2]. AM is sutured onto the ocular surface or into the defect area to treat corneal ulcerations of
different origin and of varying depth up to perforation [3, 4], preventing progress of the disease
and the eventual need for further surgical interventions like keratoplasty, conjunctival cover-
age, or tarsorraphy. Recently, AM transplantation was also successfully applied as an adjuvant
therapy for treating bullous and band keratopathy [5, 6].
AM is composed of extracellular matrix proteins like collagens, laminins, and fibronectin
[7], and releases anti-inflammatory interleukins which suppress various pro-inflammatory fac-
tors [8, 9]. Furthermore, AM contains and releases anti-angiogenic factors [8], and mediates
epithelial proliferation by various growth factors [10]. Although there is growing evidence for
the beneficial effects of AM, it is still not fully understood how it supports wound healing. Pre-
sumably, AMmay serve as a reservoir for beneficial factors that are released upon tissue degra-
dation. This release would lead to a wash-out of factors after transplantation. Therefore, a
weekly change of AM is recommended in order to sustain healing of epithelial defects [11].
Furthermore, AMmay also act as a guide rail to enhance re-epithelialization of the ocular sur-
face [11].
From a clinical point of view, surgical manipulation of the inflamed or diseased ocular sur-
face implies additional trauma or wounding, and side effects such as conjunctival bleeding or
scarring cannot be excluded. This renders a weekly repetition of the surgical procedure not fea-
sible. In some cases a surgical AM coverage is not possible due to logistical reasons, e.g. in the
early phase of life-threatening bullous skin diseases like Lyell syndrome or Stevens-Johnson
syndrome, or in multimorbid patients. One possibility to avoid surgical manipulation is to fix
AM with fibrin glue onto the diseased ocular surface [12], but in a recent case report fibrin glue
application onto the diseased corneal surface was considered disadvantageous, because it may
mask the underlying lesion and may interfere with drug penetration [13]. The optimum would
be a completely non-surgical procedure with minimal manipulation of the diseased conjuncti-
val or corneal tissue. Therefore, we designed a system for sutureless AM coverage in which AM
is mounted between two rings (AmnioClip), which can be applied like a contact lens onto the
patient eye and which allows for weekly application of new AM without surgical intervention.
During the developmental process, different prototypes were designed and tested on healthy
subjects. The final prototype was successfully tested in a first pilot study of patients with corne-
al diseases. Additionally, the biological features of AM before and after therapeutic application
were examined. A manufacturing license according to national legal obligations was obtained.
Materials and Methods
The protocol for this trial and supporting TREND checklist are available as supporting infor-
mation; see S1 Checklist, S1 Protocol, and S2 Protocol (German).
Development and manufacture of AmnioClip
Three different prototypes consisting of an inner and an outer ring for mounting AM in be-
tween the rings were developed by computer-aided design (CAD) according to clinical require-
ments regarding fit and tolerance. The first two prototypes were manufactured at the
workshop of the Leibniz-Institute for Polymer Research Dresden (IPF Dresden, Germany) on
a computerized numerical control (CNC) lathe and were made of polycarbonate (PC) or
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polyether ether ketone (PEEK) with a truncated, cone-shaped form, allowing the assembled
rings to rest tangentially on the sclera. The third prototype, AmnioClip, had an outer silicone
ring manufactured as a pressed part under clean room conditions (KET Kunststoff- und Elast-
technik GmbH, Liegau-Augustusbad, Germany) and an inner steel ring made from bended
wire (FBtec Knoche & Mork GmbH, Hagen, Germany) that was laser welded (FocusControl,
Braunschweig, Germany) (design and assembly of AmnioClip by FORTECH GmbH, Dresden,
Germany). In addition, a sterilizable device for facilitated mounting of AM into AmnioClip
was designed (FORTECH GmbH), manufactured in single parts on a CNC lathe (Kunstoff-
technik Dresden, Dresden, Germany), and assembled (FORTECH GmbH). The rings were
sterilized by electron beam (25 Gy; Synergyhealth, Radeberg, Germany) according to a validat-
ed procedure (KET Kunststoff und Elasttechnik GmbH) in heat sealed FLEXOPEEL steriliza-
tion bags (Kobusch-Sengewald, Warburg, Germany; Steripack 85 heat sealer, Münchner
Medizin Mechanik, Munich, Germany) under clean room conditions.
Testing on healthy subjects
During development of the ring system, the various prototypes were tested on healthy subjects
(IK, KE) to examine wearing comfort. The clipped rings without AM were applied to the ocular
surface after local anesthesia (0.5% proxymetacaine eye drops) under slit lamp control. Rings
were left on the ocular surface for 1–2 hours. Wearing comfort was estimated in dependence
on foreign body sensation and induction of pain.
Patients and ethics statement
We conducted a monocentric pilot study at our clinic with a seven day-wearing period of
AmnioClip to prove safety, wearability and fit of AmnioClip as a prerequisite to obtain a regu-
latory approval. From February 2011 to August 2013, seven patients were included and fol-
lowed-up in the pilot study (expanded access) (see Table 1). One patient (no. 5) received
Table 1. Diagnosis and application data.
Patient Diagnosis Number of
applications
Eye Duration
(days)
Fitting and performance of AmnioClip
1 chronic transplant erosion 2 R 4 good
R 6 good
2 contact lens associated keratitis with erosion 1 L 6 good, adapted instantly
3 progressive corneal scarring after Herpes
keratitis
2 R 7 good, adapted instantly
R 7 good, adapted instantly
4 corneal surface disorder and Fuchs endothelial
dystrophy
2 R 6 good, adapted instantly
R 6 good, at day 6 AM slackened
5 corneal surface disorder and Fuchs endothelial
dystrophy
5 R 6 good, adapted instantly
L 7 good, adapted instantly
R 4 good, adapted instantly, ring fell out after
4 days
L 4 good, adapted instantly, at day 4 AM
slackened
R 7 good, adapted instantly
6 chronic erosion, beginning ulceration 1 R 7 good
7 corneal ulcer 1 R 14 good, adapted instantly
doi:10.1371/journal.pone.0125035.t001
Sutureless Application of Amniotic Membrane
PLOS ONE | DOI:10.1371/journal.pone.0125035 May 8, 2015 3 / 13
treatment on both eyes due to a bilateral affection, so that altogether 8 eyes of 7 patients were
treated. Four of these 7 patients received a repeated treatment: Patients no. 1, no. 3, and no. 4
received AM treatment twice, and patient no. 5 received 5 AMs (3 applications on the right eye
and 2 applications on the left eye), summed up 14 AM applications altogether. All patients
gave informed consent to participate in the study in written form. Consent was also given to
use the data obtained in this study in electronic and in written form. Patients were anonymized
according to an enrolment log. Detail has been removed from case descriptions to ensure ano-
nymity. According to national laws it is stipulated to inform the respective ethics committee,
but it was not necessary to register the study in an official registry or to obtain an ethics com-
mittee vote, because it was an expanded access study (“Heilversuch”). Despite this, we prospec-
tively obtained a vote of the ethics committee. Study design and patient information form were
approved by the local ethics committee (ethics committee of the regional medical association;
approval no. EK-BR-50/10-1, date of approval December 10th, 2010). In addition, the study
was registered at www.clinicaltrials.gov (ID no. NCT02168790). The authors confirm that all
ongoing and related trials for this drug/intervention are registered as required by national laws.
Assembly of AmnioClip and AM, placement on the eye and follow-up
examinations
Cryopreserved AMs were obtained from the cornea and tissue bank Schwerin (HELIOS Klini-
ken Schwerin, Germany) in cooperation with the DGFG (Deutsche Gesellschaft fuer Gewebe-
transplantation gGmbH- German Association for Tissue Transplantation, non-profit
organization, Hannover, Germany). AMs were thawed immediately before use, and mounted
into AmnioClip using the accessory mounting device. Overlapping ends were cut off and
stored in liquid nitrogen for further analyses. After local anaesthesia with 0.5% proxymetacaine
eye drops, AmnioClip with AM was applied onto the ocular surface into the palpebral fissure.
In some cases, a lid retractor was used to facilitate placement of the ring. Individual therapy re-
gimes with local antibiotic, steroidal or caring/supporting eye drops were continued after inser-
tion of AmnioClip. Patients were followed-up the next day after insertion of AmnioClip and
then every second day by slit lamp examination. AMs were removed at day seven and patients
were presented a final questionnaire to evaluate wearing comfort. In some cases, preservative-
free sodium fluorescein (1.75 mg/ml) was applied as eye drops to the ocular surface to examine
corneal erosion sizes under blue light. Findings were photodocumented using the Imaging
Module IM 900 (Haag-Streit Deutschland GmbH, Wedel, Germany).
Histochemical analysis
Ten AMs were examined by histochemical staining with hematoxylin-eosin (HE) after being
worn by patients for treating chronic corneal transplant erosion (2x), contact lens associated
keratitis with erosion (1x), progressive corneal scarring after Herpes keratitis (2x), and corneal
endothelial dystrophy with epithelial edema (5x). Protruding ends that were cut off after
mounting and stored in liquid nitrogen served as controls. Membranes were fixed in 10% for-
malin, embedded in paraffin and 5μm sections were cut on a rotary microtome (JUNG RM
2065 by Leica, Wetzlar, Germany). The sections were deparaffinized in descending ethanol
concentrations to water and stained with Mayer´s hemalaun and eosin (VWR International
GmbH, Darmstadt, Germany) according to routine histochemical protocols. Stained sections
were dehydrated in ascending ethanol concentrations to xylol, and mounted in DePex (Serva
Electrophoresis GmbH, Heidelberg, Germany). Sections were documented on a Nikon Opti-
phot-2 microscope with a Nikon DS-Fi1 camera driven by NIS-Elements software (Nikon
GmbH, Duesseldorf, Germany).
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RNA isolation, reverse transcription and real-time PCR
Total RNA was isolated from AMs immediately after cryopreservation and thawing (AM),
from AMs as tissue residues after mounting before transplantation (AM-transplant), and from
AMs after being applied on the ocular surface for up to 7 days (AM-explant) using the RNeasy
Plus Micro Kit (Qiagen, Hilden, Germany). Equal amounts of RNA were reverse transcribed
using SuperScript II Reverse Transcriptase with random hexamer primers according to the
manufacturer's instructions (Life Technologies, Darmstadt, Germany). Vascular endothelial
growth factor-A (isoform VEGF-A165a), hepatocyte growth factor (HGF), fibroblast growth
factor 2 (FGF-2) and pigment epithelium-derived factor (PEDF) mRNA expression was ana-
lyzed by real-time PCR using specific primers (Table 2), GoTaq qPCR Master Mix (Promega,
Mannheim, Germany) and an iCycler (Bio-Rad, Munich, Germany) as described previously
[14]. Briefly, after initial denaturation at 95°C for 8 min sequences were amplified in 40 cycles
of denaturation at 95°C for 20 s, annealing at 58°C for 45 s, and extension at 72°C for 20 s. The
translation elongation factor 2 (EF2) was used as reference gene for cDNA content normaliza-
tion. After final extension at 72°C for 2 min, melt-curve analysis was performed to ensure a sin-
gle amplified product in each reaction. Raw data were analyzed with iQ5 software (Bio-Rad,
Munich, Germany), and evaluated using a mathematical model of relative expression ratio in
real-time PCR under constant reference gene expression [15]. All assays were performed at
least in triplicate and analyzed statistically by one-way ANOVA using SPSS, version 12.0
(SPSS, Chicago, IL, USA). Significance was accepted at p< 0.05.
Results
Development of ring prototypes and self-experiment
AmnioClip is a dual clip ring system (Fig 1A and 1B) for sutureless application of amniotic
membrane (AM) according to clinical requirements. AM is mounted between the two rings
(Fig 1C) with a specially designed, accessory mounting device (Fig 1D and 1E). In initial self-
experiments by two of the authors (IK, KE), the first two prototypes (not shown) caused a
strong foreign body sensation with irritation of the conjunctiva already within the first hour of
wearing. The stiff material was not well tolerated, and smoothening of lines and angles only
slightly improved the wearing comfort. The third prototype (AmnioClip, Fig 1) was rendered
suitable for clinical use. The outer silicone ring has a diameter of 23.1 mm, while the inner ring
has a diameter of 18.67mm. The mounted system has a profile thickness of approx. 1.76 mm
which lessens as pressure is distributed over the system during wearing, while maintaining ade-
quate form stability. Depending on experience and with assistance, the assembly of AM into
the clip ring system took approx. 5–20 minutes. During mounting, AMs were moistened with
BSS. The application onto the ocular surface and insertion into the fornices then took about an-
other 3–5 minutes. Experimental wearing by healthy subjects (IK, KE) for 1–2 hours did not in-
duce foreign body sensation or irritation of the ocular surface due to the soft silicone material.
Therefore, a small series of AmnioClip were produced and used on a small group of patients in-
dicated for AM transplantation in a pilot study at the Department of Ophthalmology, Klini-
kum Chemnitz gGmbH.
Clinical pilot study
Seven patients / eight eyes (six unilateral treatments, one bilateral treatment) were included
into a clinical pilot study (expanded access study to clear safety issues) (Table 1). The average
age of the patients (five women, two men) was 56.7 ± 22.5 years (24–85 years). The average du-
ration of sutureless AM application with AmnioClip was 6.5 ± 2.4 days (4–14 days). In four
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cases AM application with AmnioClip was repeated: Three patients received two consecutive
treatments in one eye, and one patient received three consecutive treatments in the right eye
and in addition and alternating to these also received two consecutive treatments in the left
eye, resulting in 14 applications altogether. Patients were informed about the indication for
AM transplantation and could choose between conventional treatment (AM sutured to the
conjunctiva) or sutureless application with AmnioClip as participants in the pilot study. All pa-
tients that decided for sutureless AM application gave their written consent to participate in
the study after being provided detailed information. AMs were placed with the stromal side to
the ocular surface, as described by Dua et al. [4]. Findings were recorded every second day and
Table 2. Primers used for gene expression analysis by real-time PCR.
Gene Primers Sequence, 5’-3’
VEGF-A165a sense cttgccttgctgctctacctc
antisense ggcacacaggatggcttga
HGF sense aacaatgcctctggttcc
antisense cgaaggcaaaaagctgtg
FGF2 sense gagaagagcgaccctcac
antisense cagctcttagcagacattgg
PEDF sense cccgctggactatcacctta
antisense ccctcgggttttcttctagg
EF2 sense atcctcaccgacatcaccaag
antisense ctgctctggacactggatctc
doi:10.1371/journal.pone.0125035.t002
Fig 1. Components of AmnioClip andmounting device. A) AmnioClip, disassembled, left: outer silicone
ring, right: inner steel ring; B) AmnioClip, assembled without AM, view from the inner (ocular) side; C)
AmnioClip, assembled with AM, view from the inner (ocular) side, D) mounting device, open position allowing
placement of the rings and AM; E) mounting device, closed “mounting” position.
doi:10.1371/journal.pone.0125035.g001
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assessed with an evaluation form specifically designed for this pilot study after the intended
wearing period. AM was removed after an intended wearing period of 6–7 days. In two cases
AmnioClip fell out of the eye after four days without ocular injury. In another case the AM was
torn in the middle at day four of wearing. One patient showed very good tolerance and retained
AmnioClip for 14 days.
All patients reported that they needed to familiarize with the perception of AmnioClip at
first day of wearing. Overall, patients reported a very good tolerance of AmnioClip (Table 3)
and were satisfied with the effects of AM already after a few days of treatment except for one
patient who did not experience subjective benefit and improvement of symptoms. Complica-
tions were not observed. Generally, all corneal indications showed improvement after treat-
ment, and morphological complications could not be observed.
The documented data were submitted by FORTECH GmbH and the DGFG to the respec-
tive authorities in order to achieve a CE certification for AmnioClip. AmnioClip is covered by
patents (DE102006019017A1, EP2004115A1, US20090143792; EP 13157162.2, FORTECH
GmbH), and CE certified. The CE mark, which states that the AmnioClip meets EU safety,
health and environmental protection requirements, was obtained in September 2013. The tis-
sue preparation (AM) "Humane Amnionmembran, kryokonserviert, Schwerin" (“human am-
niotic membrane, cryopreserved, Schwerin”), has an authorization of the national authorities
(PEI.G.11579.01.1, Pharmaceutical Entrepreneur—DGFG).
Case reports
Principally all cases could be shown, but obtaining a comparable quality of clinical photographs
of patient eyes who suffer from ocular surface disorders is very difficult, because these patients
have a strong protective reflex to close their eye lids and frequent nictitating. Therefore, two
cases were chosen to exemplary display the fit and effect of AmnioClip on a diseased
ocular surface.
Case 1. A 85-year old patient with unilateral pain in the right eye was diagnosed with mild
conjunctival irritation and a 1x1mm epithelial erosion due to corneal decompensation after
multiple retinal surgeries with silicone oil instillation. Local medication was set to dexpanthe-
nol 50mg/ml eye drops every 2 hours during the day and ointment 50mg/g for the night and
antibiotic treatment with ofloxacin 3 mg/ml eye drops every 2 hours during the day. The ero-
sion increased in size despite local medication, and intensifying the treatment regime did not
improve the symptoms. Treatment was then complemented by sutureless AM application with
AmnioClip for 7 days (Fig 2), and local medication was reduced to 5x/day dexpanthenol and
ofloxacin eye drops. Besides a mild sensation of pressure, no further irritations were observed
by the examiner or reported by the patient. After removal of the AM the size of the erosion was
distinctly reduced, so that a causal therapy to remove the silicone oil could be initiated.
Case 2. A 79-year old patient with corneal ulceration and a deep stromal defect at the 5 o
´clock position was indicated for a double-layered AM transplantation. Firstly, a small AM
inlay was sutured into the corneal stromal defect and the second layer was applied sutureless
with AmnioClip (Fig 3), covering the entire cornea and adjacent conjunctiva. This approach
Table 3. Treatment tolerance; n = 14.
Subjective perception Foreign body sensation (n) Pain (n)
none 1 11
mild 13 (infrequently) 3 (infrequently)
moderate to considerable 0 0
doi:10.1371/journal.pone.0125035.t003
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was chosen to be able to exchange the second transplant within short intervals, if needed. The
sutured AM patch was successfully supported by the second AM over a period of two weeks
Fig 2. Sutureless application of AM for treating refractory epithelial erosion (case 1, patient #6). A) Slit lamp examination and B) fluorescein
demonstration of the corneal erosion before sutureless AM application, arrow indicates the lesioned site; C,D) slit lamp control of AM fit at days 3 and 5 of
wearing, arrow in D points on AmnioClip; E) slit lamp control and F) fluorescein demonstration of the corneal surface after removal of the AM at day 7, the
arrow indicates the reduced lesion.
doi:10.1371/journal.pone.0125035.g002
Fig 3. Sutureless application of AM for treating corneal ulceration and a deep stromal defect (case 2, patient #7). A) Slit lamp examination and B,C)
fluorescein demonstration of the deep corneal ulceration before sutureless AM application, the arrow in B indicates the corneal ulceration site; D) slit lamp
control of AM fit before removal, the arrow points on AmnioClip which was used for applying AM in sandwich technique, E) slit lamp examination and F)
fluorescein demonstration of the stable AM inlay after removal of AmnioClip at day 14, the arrow indicates the AM inlay after removal of AmnioClip.
doi:10.1371/journal.pone.0125035.g003
Sutureless Application of Amniotic Membrane
PLOS ONE | DOI:10.1371/journal.pone.0125035 May 8, 2015 8 / 13
without complications. This approach was well tolerated and the AmnioClip was replaced with
a bandage type contact lens during the third week.
Histological examination of amniotic membranes after therapeutic
application
Of the 14 AMs that were applied to the diseased ocular surface of patients, 10 were histological-
ly analyzed. The AMs appeared intact with a loosened stroma. The parts of the AMs that were
clipped into the holding device had a condensed stroma, but the amniotic epithelium still ap-
peared normal (Fig 4A). Some AMs were devoid of amniotic epithelium (Fig 4B), while others
were partially covered by a single layer of small squamous to cuboidal epithelial cells with flat
to oval nuclei (amniotic epithelium; Fig 4C). On 4 of 10 membranes a multi-layered epithelium
composed of prismatic and much larger cells with big round nuclei could be seen, which were
presumed to be patient-derived epithelial cells, and not of amniotic origin (Fig 4D–4F).
Expression of growth factors in AMs immediately before and after
transplantation
Sufficient amounts of RNA could be isolated from stored AMs immediately after thawing
(AM), or after mounting and tailoring of AMs before transplantation (AM-transplant). In
Fig 4. Morphology of AMs after therapeutic application. A) AM appears condensed at the site of the ring;
B) AM without epithelium (patient #3 second application); C) some AMs retained their own monolayered
epithelium (patient #5 first application L); D) same AM as in C, showing a double-layered epithelium with
larger cells at the stromal side which faced the patient eye during application; E) some AMs had a multi-
layered stratified epithelium with big, cuboidal cells with large round nuclei on the epithelial side which faced
the air during application (patient #3 first application); F) same AM as in E, here the stratified epithelium at the
epithelial side appeared bulky and the cells were of irregular size. HE staining; es: epithelial side; ss: stromal
side; scale bar in A 100 μm, scale bar in B-F 50 μm.
doi:10.1371/journal.pone.0125035.g004
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contrast, after being worn for one week, successful RNA isolation could not be achieved from
explanted AMs (AM-explant) (Fig 5A; n3). Therefore, mRNA expression of different growth
factors was determined in AMs immediately after storage (AM) and after mounting and tailor-
ing for transplantation (AM-transplant). Messenger RNA of VEGF-A, HGF, FGF-2, and PEDF
was quantified in whole RNA extracts (Fig 5B). VEGF-A and PEDF mRNA could be detected
in cryopreserved AMs immediately after thawing and on a lower level also in AMs after me-
chanical handling before transplantation, while mRNA expression of HGF and FGF-2 was
only detectable in freshly thawed AM, but not after handling.
Discussion
Multifaceted utilization of AM is aggravated by the necessity for surgical application. A suture-
less application technique would have many advantages. Complications due to surgical inter-
vention, like injury and bleeding of the conjunctiva, can be avoided. General or local
anaesthesia is not necessary except for the use of anaesthetic eye drops. A sutureless application
could be performed as an ambulatory treatment not only at an ophthalmological clinic, but
also e.g. at intensive care units in cases of GvHD or bullous epitheliopathies like Stevens-
Fig 5. Growth factor expression in AMs at different time points during processing and use. A)
Concentration of RNA from amniotic membranes directly after cryopreservation (AM), AMs after mechanical
handling before transplantation (AM-transplant), or AMs after being worn on the ocular surface for one week
(AM-explant) (n3). B) mRNA of vascular endothelial growth factor-A (isoform VEGF-A165a), hepatocyte
growth factor (HGF), fibroblast growth factor 2 (FGF-2) and pigment epithelium-derived factor (PEDF) in
amniotic membranes immediately after thawing (AM), or AMs after mechanical handling before
transplantation (AM-transplant). Bars represent mean ± SEM of three or more measurements. *p<0.05 vs.
AM.
doi:10.1371/journal.pone.0125035.g005
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Johnson syndrome. Expended AMs could easily be removed or replaced by new ones. More-
over, AM could be applied more often and in shorter intervals onto the patient eye, allowing
for the utilization of its beneficial anti-inflammatory and wound-healing features without re-
peatedly imposing a surgical trauma. Handling of the membrane is also facilitated by simply
mounting it into the clip ring system with a specially designed mounting device.
Publication of the development of AmnioClip and the resulting clinical data were delayed
due to patenting the system. Parallel to developing AmnioClip, two similar systems were re-
cently developed and published. ProKera was developed in the USA and is delivered as a
ready-to-use product with AMmounted in a form stable PMMA ring system in a 1/1 solution
of DMEM and glycerol with ciprofloxacin and amphotericin B [16, 17]. Tolerance of this sys-
tem was described in a small clinical study [18]. Another ring system is comprised of a perfo-
rated titanium ring to which the AM is sutured [19]. All three systems can be used to apply
AM to the ocular surface without surgical intervention. With AmnioClip the AM can be ap-
plied within a short time frame and no suturing is necessary. As a further advantage, Amnio-
Clip can be obtained either as a ready-to-use applicable system or as single components in case
users prefer to mount the AM themselves. The mounting device can be sterilized and is easy to
use. This enables a repeated application of AM in a patient with individual treatment time, be-
cause all parts of the system can be stored for several months (AM up to12 months at -60°C as
recommended by the DGFG). Utilization of the system without additional solutions and pre-
servatives protects the AM from a loss of active ingredients by wash-out before application.
The silicone-based ring system aids the observed good tolerance and wearing comfort of
AmnioClip. This was successfully tested in an experiment on oneself and in a pilot study on pa-
tients with diseased ocular surfaces. The DGFG plans an application for the marketing authori-
zation of the AmnioClip plus AM at the national authorities in accordance with national
statutory requirements. Furthermore, the European Commission Directive on the use and safe-
ty of cells and tissues for medical applications requires proof that the combination of amniotic
membrane with a medical device is not detrimental to the AMs biological quality, which was
examined before and after application of AM with AmnioClip.
Amniotic epithelial cells express and release growth factors which can protect corneal tissue
against apoptosis and improve regenerative processes [10]. Recently, it was shown in a mouse
model of wound healing on skin that AM exerts an anti-angiogenic effect at its epithelial side
and an angiogenic effect at its stromal side [20]. As mentioned by the authors, the reports
about the effects of AM on stimulation or inhibition of angiogenesis differ in the literature.
Until now the decision as to whether AM is placed with its epithelial or stromal side in contact
to the ocular surface is left to the surgeon [21]. Here we give evidence that the additional ex-
pression of VEGF-A, HGF, FGF-2 and PEDF. PEDF is an effective neurogenic and neuropro-
tective agent, but also a potent inhibitor of neovascularization [22], and likely accounts for the
anti-angiogenic effect of AM. Therefore, PEDF released from transplanted amniotic mem-
branes might mediate beneficial effects in the cornea as well, prohibiting vessel ingrowth into
the wounded corneal tissue. Though VEGF-A and FGF-2 promote angiogenesis and vessel
growth [23, 24], which is undesired in corneal tissue, they can act as survival factors for corneal
and neural cells as well [25, 26]. Transient expression of VEGF-A might even be beneficial by
promoting angiogenesis, vessel growth and survival of damaged cells especially in limbal re-
gions due to improved supply with nutrients and oxygen to support the limbal epithelial stem
cell niche [27]. However, VEGF-A expression is partially reduced in AM after freezing/thawing
and AM is depleted of all factors during a 7-day treatment. HGF contributes to corneal wound
healing by stimulating the proliferation of human corneal epithelial and endothelial cells [28].
Even while the HGF and FGF-2 mRNA were detected in amniotic membranes directly after
thawing, but not after mounting the membranes, preformed peptides deposited in the
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membrane stroma might be released from transplanted AM. This could initiate regenerative
processes in the state of corneal diseases. Since we could not detect a considerable amount of
mRNA in explanted AMs one week after transplantation, substantial growth of amniotic cells
or invading corneal cells on the transplanted AMs can be excluded.
In conclusion, the transplantation of AM using the novel, sutureless AmnioClip system
might provide an improved therapeutic strategy in corneal diseases.
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